Q4 EPS Forecast for Theravance Biopharma Raised by Analyst

Theravance Biopharma, Inc. (NASDAQ:TBPH) – Research analysts at Zacks Research raised their Q4 2025 earnings per share (EPS) estimates for shares of Theravance Biopharma in a note issued to investors on Monday, October 21st. Zacks Research analyst R. Department now expects that the biopharmaceutical company will earn $0.51 per share for the quarter, up from their previous forecast of $0.46. The consensus estimate for Theravance Biopharma’s current full-year earnings is ($1.04) per share.

Several other brokerages also recently weighed in on TBPH. Leerink Partners downgraded Theravance Biopharma from an “outperform” rating to a “market perform” rating and decreased their target price for the company from $15.00 to $10.00 in a research note on Tuesday, August 6th. TD Cowen reduced their price objective on Theravance Biopharma from $10.00 to $9.00 and set a “hold” rating for the company in a research report on Tuesday, August 6th. StockNews.com downgraded Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Saturday, August 10th. Leerink Partnrs downgraded Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 6th. Finally, HC Wainwright reiterated a “buy” rating and issued a $15.00 price objective on shares of Theravance Biopharma in a research report on Monday, September 16th. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $13.75.

Theravance Biopharma Stock Down 1.9 %

Shares of NASDAQ:TBPH opened at $8.63 on Tuesday. The business has a 50 day moving average price of $8.21 and a 200 day moving average price of $8.76. Theravance Biopharma has a twelve month low of $7.44 and a twelve month high of $11.71. The company has a market cap of $422.18 million, a price-to-earnings ratio of -9.38 and a beta of 0.25.

Theravance Biopharma (NASDAQ:TBPH) last announced its earnings results on Monday, August 5th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.25). Theravance Biopharma had a negative net margin of 73.61% and a negative return on equity of 21.29%. The business had revenue of $14.26 million for the quarter, compared to the consensus estimate of $15.81 million. During the same quarter in the previous year, the company earned ($0.28) EPS.

Insider Transactions at Theravance Biopharma

In related news, major shareholder Eli Samaha bought 999,800 shares of the company’s stock in a transaction dated Wednesday, August 7th. The stock was acquired at an average cost of $7.80 per share, with a total value of $7,798,440.00. Following the acquisition, the insider now owns 9,511,150 shares in the company, valued at approximately $74,186,970. This represents a 0.00 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 6.90% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Theravance Biopharma

Hedge funds and other institutional investors have recently bought and sold shares of the business. Hsbc Holdings PLC acquired a new stake in Theravance Biopharma during the 2nd quarter valued at $108,000. Ballentine Partners LLC acquired a new stake in Theravance Biopharma during the 3rd quarter valued at $104,000. XTX Topco Ltd bought a new position in Theravance Biopharma in the 2nd quarter valued at $129,000. State Board of Administration of Florida Retirement System boosted its position in Theravance Biopharma by 28.2% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 22,671 shares of the biopharmaceutical company’s stock valued at $203,000 after buying an additional 4,990 shares during the last quarter. Finally, BNP Paribas Financial Markets boosted its position in Theravance Biopharma by 30.7% in the 1st quarter. BNP Paribas Financial Markets now owns 33,458 shares of the biopharmaceutical company’s stock valued at $300,000 after buying an additional 7,851 shares during the last quarter. 99.10% of the stock is owned by institutional investors and hedge funds.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.